New insights into the diagnosis and treatment of dry eye

Ocular Surface

Volumn 2, Issue 2, 2004, Pages 59-75

  Dogru, Murat ^a   Tsubota, Kazuo ^b  

^a TOKYO DENTAL COLLEGE   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti inflammatory agents; Aqueous deficiency; Autoimmune disorder; Dry eye syndrome; Heredity; Inflammation; Keratoconjunctivitis sicca; Sjogren syndrome; Tear stability analysis system; Visual acuity meter

Indexed keywords

ALPHA2 INTERFERON; ANDROGEN; ANTIINFLAMMATORY AGENT; AQUAPORIN 5; ARTIFICIAL TEAR; CALCIUM CARBONATE; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN A; DICLOFENAC; DIQUAFOSOL; GROWTH HORMONE; HLA DQ ANTIGEN; HLA DR5 ANTIGEN; HYALURONIC ACID; HYDROXYPROPYLMETHYLCELLULOSE; IMMUNOSUPPRESSIVE AGENT; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; METHYLPREDNISOLONE; MUCIN; MUSCARINIC RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; PILOCARPINE; RIBONUCLEOPROTEIN; T LYMPHOCYTE RECEPTOR; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

APOPTOSIS; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG RECEPTOR BINDING; DRY EYE; GENETIC PREDISPOSITION; HUMAN; KERATINIZATION; MEDICAL TECHNOLOGY; NON INVASIVE MEASUREMENT; NONHUMAN; PATHOGENESIS; PATIENT COUNSELING; REVIEW; SIDE EFFECT; SJOEGREN SYNDROME; SPECTACLES; SYMPTOMATOLOGY; TEAR FILM; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL SYSTEM EXAMINATION;

EID: 24644457694     PISSN: 15420124     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1542-0124(12)70145-3     Document Type: Review

References (121)

1. Smith G. Pathology of the tear film, in Korb DR, Craig J, Doughty M, et al (eds). The tear film: structure, function and clinical examination. Oxford, Butterworth Heinemann, 2002, pp104-25
2. Lemp M. Report of the National Eye Institute/Industry Workshop on Clinical Trials and Dry Eyes. CLAO J 1995;21:221-32
3. Doughty M. Introduction, in Korb DR, Craig J, Doughty M, et al (eds). The tear film: structure, function and clinical examination. Oxford, Butterworth Heinemann, 2002, pp 1-3
4. Schein OD, Munoz B, Tielsch JM, et al. Prevalence of dry eye among the elderly. Am J Ophthalmol 1997;124:723-8
5. McCarty CA, Bansal AK, Livingston PM, et al. The epidemiology of dry eye in Melbourne, Australia. Ophthalmology 1998;105:1114-9
6. Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol 2000;118:1264-8
7. Schaumberg DA, Sullivan DA, Dana MR. Epidemiology of dry eye syndrome. Adv Exp Med Biol 2002;506(Pt B):989-8
8. Hikichi T, Yoshida A, Fukui Y, et al. Prevalence of dry eye in Japanese eye centers. Graefes Arch Clin Exp Ophthalmol 1995;233:555-8
9. Silmon AJ, Rooney AK. Epidemiology of Sjögren's syndrome. Jonkoping Hygiea 1999, pp 53-7
10. Fox RI, Saito I. Criteria for diagnosis of Sjögren's syndrome. Rheum Dis Clin North Am 1994;20:391-407
11. Vitali C, Moutsopoulos HM, Bombardieri S. The European Community Study Group on diagnostic criteria for Sjögren's syndrome. Sensitivity and specificity of tests for ocular and oral involvement in Sjögren's syndrome. Ann Rheum Dis 1994;53:637-47
12. Eguchi K. The manual of Sjögren's syndrome diagnosis by Japanese Medical Society for Sjögren's syndrome. Nagasaki, Ryoin Publishers, 2000
13. Stern ME, Beuerman RW, Fox RI, et al. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea 1998;17:584-9
14. Sullivan DA, Wickham LA, Rocha EM, et al. Androgens and dry eye in Sjögren's syndrome. Ann N Y Acad Sci 1999;876:312-24
15. Sullivan DA, Belanger A, Cermak JM, et al. Are women with Sjögren's syndrome androgen-deficient? J Rheumatol 2003;30:2413-9
16. Kroemer G, Martinez C. Cytokines and autoimmune disease. Clin Immunol Immunopathol 1991;61:275-95
17. Pepose JS, Akata RF, Pflugfelder SC, et al. Mononuclear cell phenotypes and immunoglobulin gene rearrangements in lacrimal gland biopsies from patients with Sjögren's syndrome. Ophthalmology 1990;97:1599-1605
18. van Bijsterveld OP, Kruize AA, Bleys RL. Central nervous system mechanisms in Sjögren's syndrome. Br J Ophthalmol 2003;87:128-30
19. Jones DT, Monroy D, Ji Z, et al. Sjögren's syndrome: cytokine and Epstein-Barr viral gene expression within the conjunctival epithelium. Invest Ophthalmol Vis Sci 1994;35:3493-3504
20. Baudouin C. The pathology of dry eye. Surv Ophthalmol 2001;45:S211-220
21. Halse A, Tengner P, Wahren-Herlenius M, et al. Increased frequency of cells secreting interleukin-6 and interleukin-10 in peripheral blood of patients with primary Sjögren's syndrome. Scand J Immunol 1999;49:533-8
22. Saito I, Haruta K, Shimuta M, et al. Fas ligand-mediated exocrinopathy resembling Sjögren's syndrome in mice transgenic for IL-10. J Immunology 1999;162:2488-94
23. Hulkkonen J, Pertovaara M, Antonen J, et al. Genetic association between interleukin-10 promoter region polymorphisms and primary Sjögren's syndrome. Arthritis Rheum 2001;44:176-9
24. Limaye V, Lester S, Downie-Doyle S, et al. Polymorphisms of the interleukin 10 gene promoter are not associated with anti-Ro autoantibodies in primary Sjögren's syndrome. J Rheumatol 2000;27:2945-6
25. Perrier S, Coussediere C, Dubost JJ, et al. IL-1 receptor antagonist (IL-1RA) gene polymorphism in Sjögren's syndrome and rheumatoid arthritis. Clin Immunol Immunopathol 1998;87:309-13
26. Jean S, Quelvennec E, Alizadeh M, et al. DRB1*15 and DRB1*03 extended haplotype interaction in primary Sjögren's syndrome genetic susceptibility. Clin Exp Rheumatol 1998;16:725-8
27. Jones DT, Monroy D, Ji Z, et al. Alterations of ocular surface gene expression in Sjögren's syndrome, in Adv Exp Med Biol 1998;438:533-6
28. Bjerrum KB. Snake-like chromatin in conjunctival cells of normal elderly persons and of patients with primary Sjögren's syndrome and other connective tissue diseases. Acta Ophthalmol Scand 1995;73:33-6
29. Pflugfelder SC, Jones D, Ji Z, et al. Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjögren's syndrome keratoconjunctivitis sicca. Curr Eye Res 1999;19:201-11
30. Pflugfelder SC, Tseng SC, Yoshino K, et al. Correlation of goblet cell density and mucosal epithelial membrane mucin expression with rose bengal staining in patients with ocular irritation. Ophthalmology 1997;104:223-35
31. Hayashi Y, Arakaki R, Ishimaru N. The role of caspase cascade on the development of primary Sjögren's syndrome. J Med Invest 2003;50:32-8
32. Ozkan ED, Lee FS, Ueda T. A protein factor that inhibits ATP-dependent glutamate and gamma-aminobutyric acid accumulation into synaptic vesicles: purification and initial characterization. Proc Natl Acad Sci U S A 1997;94:4137-42
33. Tsubota K, Fujita H, Tadano K, et al. Abnormal expression and function of Fas ligand of lacrimal glands and peripheral blood in Sjögren's syndrome patients with enlarged exocrine glands. Clin Exp Immunol 2002;129:177-82
34. Tsubota K, Fujita H, Tsuzaka K, et al. Quantitative analysis of lacrimal gland function, apoptotic figures, Fas and Fas ligand expression of lacrimal glands in dry eye patients. Exp Eye Res 2003;76:233-40
35. Green JE, Hinrichs SH, Vogel J, et al. Exocrinopathy resembling Sjögren's syndrome in HTLV-1 tax transgenic mice. Nature 1989;341:72-4
36. Koike K, Moriya K, Ishibashi K, et al. Sialadenitis histologically resembling Sjögren syndrome in mice transgenic for hepatitis C virus envelope genes. Proc Natl Acad Sci USA 1997;94:233-6
37. Sixbey JW, Yao QY. Immunoglobulin A-induced shift of Epstein-Barr virus tissue tropism. Science 1992;255:1578-80
38. Pflugfelder SC, Crouse C, Pereira I, et al. Amplification of Epstein-Barr virus genomic sequences in blood cells, lacrimal glands, and tears from primary Sjögren's syndrome patients. Ophthalmology 1990;97:976-84
39. Crouse CA, Pflugfelder SC, Cleary T, et al. Detection of Epstein-Barr virus genomes in normal human lacrimal glands. J Clin Microbiol 1990;28:1026-32
40. Tsubota K, Fujishima H, Toda I, et al. Increased levels of Epstein-Barr virus DNA in lacrimal glands of Sjögren's syndrome patients. Acta Ophthalmol Scand 1995;73:425-30
41. Pflugfelder SC, Huang AJ, Feuer W, et al. Conjunctival cytologic features of primary Sjögren's syndrome. Ophthalmology 1990;97:985-91
42. Reveille JD, Wilson RW, Provost TT, et al. Primary Sjögren's syndrome and other autoimmune diseases in families. Prevalence and immunogenetic studies in six kindreds. Ann Intern Med 1984;101:748-56
43. Koivukangas T, Simila S, Heikkinen E, et al. Sjögren's syndrome and achalasia of the cardia in two siblings. Pediatrics 1973;51:943-5
44. Mason AM, Golding PL. Multiple immunological abnormalities in a family. J Clin Pathol 1971;24:732-5
45. Sabio JM, Milla E, Jimenez-Alonso J. A multicase family with primary Sjögren's syndrome. J Rheumatol 2001;28:1932-4
46. Bolstad AI, Haga HJ, Wassmuth R, et al. Monozygotic twins with primary Sjögren's syndrome. J Rheumatol 2000;27:2264-6
47. Tanaka A, Igarashi M, Kakinuma M, et al. The occurrence of various collagen diseases in one family: a sister with ISSc, PBC, APS, and SS and a brother with systemic lupus erythematosus. J Dermatol 2001;28:547-53
48. Reveille JD, Arnett FC. The immunogenetics of Sjögren's syndrome. Rheum Dis Clin North Am 1992;18:539-50
49. Nepom GT. MHC and autoimmune diseases. Immunol Ser 1993;59:143-64
50. Merriman TR, Todd JA. Genetics of autoimmune disease. Curr Opin Immunol 1995;7:786-92
51. Tomlinson IP, Bodmer WF. The HLA system and the analysis of multifactorial genetic disease. Trends Genet 1995;11:493-8
52. Loiseau P, Lepage V, Djelal F, et al. HLA class I and class II are both associated with the genetic predisposition to primary Sjögren syndrome. Hum Immunol 2001;62:725-31
53. Manthorpe R, Morling N, Platz P, et al. HLA-D antigen frequencies in Sjögren's syndrome. Differences between the primary and secondary form. Scand J Rheumatol 1981;10:124-8
54. Papasteriades CA, Skopouli FN, Drosos AA, et al. HLA-alloantigen associations in Greek patients with Sjögren's syndrome. J Autoimmun 1988;1:85-90
55. Harley JB, Reichlin M, Arnett FC, et al. Gene interaction at HLA-DQ enhances autoantibody production in primary Sjögren's syndrome. Science 1986;232:1145-7
56. Kerttula TO, Collin P, Polvi A, et al. Distinct immunologic features of Finnish Sjögren's syndrome patients with HLA alleles DRB1* DQA1*0501, and DQB1*0201. Alterations in circulating T cell receptor gamma/delta subsets. Arthritis Rheum 1996; 39:1733-9
57. Hadj Kacem H, Kaddour N, Adyel FZ, et al. HLA-DQB1 CAR1/ CAR2, TNFa IR2/IR4 and CTLA-4 polymorphisms in Tunisian patients with rheumatoid arthritis and Sjögren's syndrome. Rheumatology (Oxford) 2001;40:1370-4
58. Rischmueller M, Lester S, Chen Z, et al. HLA class II phenotype controls diversification of the autoantibody response in primary Sjögren's syndrome (pSS). Clin Exp Immunol 1998;111:365-71
59. Fei HM, Kang H, Scharf S, et al. Specific HLA-DQA and HLA-DRB1 alleles confer susceptibility to Sjögren's syndrome and autoantibody production. J Clin Lab Anal 1991;5:382-91
60. Ohlsson M, Jonsson R, Brokstad KA. Subcellular redistribution and surface exposure of the Ro52, Ro60 and La48 autoantigens during apoptosis in human ductal epithelial cells: a possible mechanism in the pathogenesis of Sjögren's syndrome. Scand J Immunol 2002;56:456-69
61. Kumagai S, Kanagawa S, Morinobu A, et al. Association of a new allele of the TAP2 gene, TAP2*Bky2 (Val577), with susceptibility to Sjögren's syndrome. Arthritis Rheum 1997; 40:1685-92
62. Tapinos NI, Polihronis M, Thyphronitis G, et al. Characterization of the cysteine-rich secretory protein 3 gene as an early-transcribed gene with a putative role in the pathophysiology of Sjögren's syndrome. Arthritis Rheum 2002;46:215-22
63. King LS, Yasui M, Agre P. Aquaporins in health and disease. Mol Med Today 2000;6:60-5
64. Verkman AS. Role of aquaporin water channels in eye function. Exp Eye Res 2003;76:137-43
65. Raina S, Preston GM, Guggino WB, et al. Molecular cloning and characterization of an aquaporin cDNA from salivary, lacrimal, and respiratory tissues. J Biol Chem 1995;270:1908-12
66. Tsubota K, Hirai S, King LS, et al. Defective cellular trafficking of lacrimal gland aquaporin-5 in Sjögren's syndrome. Lancet 2001;357:688-9
67. Ohashi Y, Ishida R, Kojima T, et al. Abnormal protein profiles in tears with dry eye syndrome. Am J Ophthalmol 2003;136:291-9
68. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8
69. Carsons S. A review and update of Sjögren's syndrome: manifestations, diagnosis, and treatment. Am J Manag Care 2001;7:S433-43
70. Ferris RL. Sjögren's syndrome, in Gold DH, Weingeist TA (eds). The eye in systemic disease. Philadelphia: JB Lippincott, 1990, pp 70-2
71. Toda I. Symptoms of dry eye, in Tsubota K (ed). Dry eye clinic. Tokyo, Igakushoin Publishers, 2000, pp 25-30
72. Begley CG, Caffery B, Chalmers RL, et al. Use of the dry eye questionnaire to measure symptoms of ocular irritation in patients with aqueous tear deficient dry eye. Cornea 2002;21:664-70
73. Sullivan RM, Cermak JM, Papas AS, et al. Economic and quality of life impact of dry eye symptoms in women with Sjögren's syndrome. Adv Exp Med Biol 2002;506:1183-8
74. Ono M. Sjögren's syndrome, in Watanabe N, Tano Y (eds). Practical ophthalmology. Tokyo, Bunkodo Publishers, 1998, pp 82-8
75. Korb DR. The tear film- its role today and in the future, in Korb DR, Craig J, Doughty M, et al (eds). The tear film: structure, function and clinical examination. Oxford, Butterworth Heinemann, 2002, pp 126-92
76. Danjo Y, Hamano T. Observation of precorneal tear film in patients with Sjögren's syndrome. Acta Ophthalmol Scand 1995; 73:501-5
77. Yokoi N, Bron AJ, Tiffany JM, et al. Reflective meniscometry: a new field of dry eye assessment. Cornea 2000;19:S37-43
78. Goto T, Zheng X, Klyce SD, et al. A new method for tear film stability analysis using videokeratography. Am J Ophthalmol 2003;135:607-12
79. Kojima T, Ishida R, Dogru M, et al. A noninvasive tear stability analysis system for the assessment of dry eyes. Invest Ophthalmol Vis Sci, in press
80. Abelson MB, Ousler GW 3rd, Nally LA, Welch D, Krenzer K. Alternative reference values for tear film break up time in normal and dry eye populations. Adv Exp Med Biol 2002;506(Pt B):1121-5
81. Goto E, Yagi Y, Matsumoto Y, et al. Impaired functional visual acuity of dry eye patients. Am J Ophthalmol 2002;133:181-6
82. Guillon J. Current clinical techniques to study the tear film and tear secretions, in Korb DR, Craig J, Doughty M, et al (eds). The tear film: structure, function and clinical examination. Oxford, Butterworth Heinemann, 2002, pp 51-81
83. Tsubota K. Reflex tearing in dry eye not associated with Sjögren's syndrome. Adv Exp Med Biol 1998;438:903-7
84. Tsubota K, Fujihara T, Takeuchi T. Soluble interleukin-2 receptors and serum autoantibodies in dry eye patients: correlation with lacrimal gland function. Cornea 1997;16:339-44
85. Tsubota K, Toda I, Yagi Y, et al. Three different types of dry eye syndrome. Cornea 1994;13:202-9
86. Toda I, Tsubota K. Practical double vital staining for ocular surface evaluation. Cornea 1993;12:366-7
87. Xu KP, Yagi Y, Toda I, Tsubota K. Tear function index. A new measure of dry eye. Arch Ophthalmol 1995;113:84-8
88. Tsubota K. Tear dynamics and dry eye. Prog Retin Eye Res 1998;17:565-96
89. de Rojas MV, Rodriguez MT, Ces Blanco JA, et al. Impression cytology in patients with keratoconjunctivitis sicca. Cytopathology 1993;4:347-55
90. Rivas L, Oroza MA, Perez-Esteban A, et al. Morphological changes in ocular surface in dry eyes and other disorders by impression cytology. Graefes Arch Clin Exp Ophthalmol 1992;230:329-34
91. Rivas L, Rodriguez JJ, Alvarez MI, et al. Correlation between impression cytology and tear function parameters in Sjögren's syndrome. Acta Ophthalmol 1993;71:353-59
92. Tsubota K, Xu KP, Fujihara T, et al. Decreased reflex tearing is associated with lymphocytic infiltration in lacrimal glands. J Rheumatol 1996;23:313-20
93. Shimazaki J. Definition and criteria of dry eye. Ganka 1995;37-765-770. Japanese
94. Gilbard JP, Rossi SR, Heyda KG. Ophthalmic solutions, the ocular surface, and a unique therapeutic artificial tear formulation. Am J Ophthalmol 1989;107:348-55
95. Ubels JL, McCartney MD, Lantz WK, et al. Effects of preservative-free artificial tear solutions on corneal epithelial structure and function. Arch Ophthalmol 1995;113:371-8
96. Tsubota K, Monden Y, Yagi Y, et al. New treatment of dry eye: the effect of calcium ointment through eyelid skin delivery. Br J Ophthalmol 1999;83:767-70
97. Tsubota K, Goto E, Fujita H, et al. Treatment of dry eye by autologous serum application in Sjögren's syndrome. Br J Ophthalmol 1999;83:390-5
98. Hori Y, Spurr-Michaud S, Russo CL, et al. Differential regulation of membrane-associated mucins in the human ocular surface epithelium. Invest Ophthalmol Vis Sci 2004;45:114-22
99. Pastor JC, Calonge M. Epidermal growth factor and corneal wound healing. A multicenter study. Cornea 1992;11:311-4
100. Fredj-Reygrobellet D, Plouet J, Delayre T, et al. Effects of aFGF and bFGF on wound healing in rabbit corneas. Curr Eye Res 1987;6:1205-9
101. Nishida T, Nakamura M, Ofuji K, et al. Synergistic effects of substance P with insulin-like growth factor-1 on epithelial migration of the cornea. J Cell Physiol 1996;169:159-66
102. Tsubota K, Yamada M, Urayama K. Spectacle side panels and moist inserts for the treatment of dry-eye patients. Cornea 1994;13:197-201
103. Tsubota K. SS dry eye and non-SS dry eye: what are the differences?, in Homma M, Sugai S, Tojo T, et al (eds). Sjögren's syndrome. State of the art. New York, Kugler Publications, 1994, pp 27-31
104. Solomon A, Dursun D, Liu Z, et al. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci 2001;42:2283-92
105. Sahlin S, Chen E, Kaugesaar T, et al. Effect of eyelid botulinum toxin injection on lacrimal drainage. Am J Ophthalmol 2000;129:481-6
106. Avisar R, Robinson A, Appel I, et al. Diclofenac sodium, 0.1% (Voltaren Ophtha), versus sodium chloride, 5%, in the treatment of filamentary keratitis. Cornea 2000;19:145-47
107. Sall K, Stevenson OD, Mundorf TK, et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 2000;107:631-9
108. Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology 2000;107:967-74
109. Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome. Ophthalmology 1999;106:811-6
110. Ferraccioli GF, Salaffi F, De Vita S, et al. Interferon alpha-2 (IFN alpha 2) increases lacrimal and salivary function in Sjögren's syndrome patients. Preliminary results of an open pilot trial versus OH-chloroquine. Clin Exp Rheumatol 1996;14:367-71
111. Stern ME, Pflugfelder SC. Inflammation in dry eye. Ocular Surface 2004;2:124-130
112. Murakami T, Fujihara T, Nakamura M, et al. P2Y(2) receptor stimulation increases tear fluid secretion in rabbits. Curr Eye Res 2000;21:782-7
113. Murakami T, Fujihara T, Horibe Y, Nakamura M. Diquafosol elicits increases in net C1(-) transport through P2Y(2) receptor stimulation in rabbit conjunctiva. Ophthalmic Res 2004;36:89-93
114. Hamano T. Dry eye treatment with eye drops that stimulate mucin production. Adv Exp Med Biol 1998;438:965-8
115. Jackson RS 2nd, Van Dyken SJ, McCartney MD, et al. The eicosanoid, 15-(S)-HETE, stimulates secretion of mucin-like glycoprotein by the corneal epithelium. Cornea 2001;20:516-21
116. Kobayashi TK, Tsubota K, Takamura E, et al. Effect of retinol palmitate as a treatment for dry eye: a cytological evaluation. Ophthalmologica 1997;211:358-61
117. Vivino FB, Al-Hashimi I, Khan Z, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch Intern Med 1999;159:174-81
118. Petrone D, Condemi JJ, Fife R, et al. A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum 2002;46:748-54
119. Toda I, Asano-Kato N, Hori-Komai Y, et al. Laser-assisted in situ keratomileusis for patients with dry eye. Arch Ophthalmol. 2002;120:1024-8
120. Solomon R, Donnenfeld ED, Perry HD. The effects of LASIK on the ocular surface. Ocular Surface 2004;2:34-44
121. Geerling G, Honnicke K, Schroder C, et al. Quality of salivary tears following autologous submandibular gland transplantation for severe dry eye. Graefes Arch Clin Exp Ophthalmol 2000;238:45-52